Dalia Quwaider

Salamanca, CL, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.

Journal: Haematologica

Published: May 05, 2023

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.

Journal: American journal of hematology

Published: November 04, 2021

RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation.

RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation.

Journal: Experimental hematology & oncology

Published: November 01, 2021

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.

Journal: Cells

Published: December 23, 2020

FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma.

FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma.

Journal: Journal of cellular and molecular medicine

Published: October 15, 2019

Factors Regulating microRNA Expression and Function in Multiple Myeloma.

Factors Regulating microRNA Expression and Function in Multiple Myeloma.

Journal: Non-coding RNA

Published: October 30, 2018

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.

Journal: Journal of hematology & oncology

Published: April 04, 2017

Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia.

Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia.

Journal: Journal of hematology & oncology

Published: January 28, 2017

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.

Journal: Journal of hematology & oncology

Published: January 19, 2017

Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.

Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 30, 2014

MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL.

MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL.

Journal: BMC cancer

Published: September 09, 2014

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 04, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026